ArticleGynecologic oncology reports2026
Recurrent epithelioid trophoblastic tumor with complete response after surgery, chemotherapy, and immunotherapy: A case report and literature review.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpithelioid trophoblastic tumor (ETT) is the rarest form of gestational trophoblastic neoplasm, accounting for 1.39-2% of gestational trophoblastic diseases. Its clinical behavior and pathogenesis remain poorly understood, and no standardized treatment guidelines currently exist, with surgery considered the most important therapeutic option. Emerging modalities, including immune checkpoint inhibitors, are under investigation. CASE PRESENTATION: We report a case of recurrent ETT achieving complete response after combined surgery, chemotherapy and immunotherapy. Notably, the primary tumor arose from the urachus, without uterine involvement; to the best of our knowledge, this presentation has not previously been reported.
conclusionThe present case highlights a novel primary site for ETT and suggests the potential efficacy of multimodal therapy, including immunotherapy, in managing recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.